培美曲塞二线治疗晚期非小细胞肺癌的临床评价

Evaluation of pemetrexed in treating advanced non-small cell Lung cancer

目的探讨培美曲塞二线治疗晚期非小细胞肺癌(NSCLC)的临床疗效。方法一线含铂方案化疗后复发的晚期NSCLC患者50例,使用培美曲塞(500 mg/m2,d1)治疗2个周期(21 d×2)。治疗前后分别采用QLQ-C30和QLQ-LCl3问卷,对患者的生活质量和症状进行评价,按RECIST标准评判临床疗效。结果部分缓解(PR)6例,稳定(SD)26例,进展(PD)18例。与治疗前比较,除社会功能外,体格、角色、情感、认知4种功能状态和整体生活质量评分均显著提高(P<0.05);乏力、食欲不振2个全身症状及5种疾病相关症状评分显著降低(P<0.05)。结论培美曲塞二线治疗晚期NSCLC能显著改善肺癌相关症状,提高患者生活质量。

Objective To investigate the efficacy of pemetrexed as a second line treatment for advanced-stage non-small cell lung cancer（NSCLC）, which was failed to the standard platium-based chemotherapies. Methods Fifty qualifed patients received pemetrexed 500 mg/m^2 , for 2 cycles with every 21 days each. Quality of life（QOL） was assessed with QLQ-30 and QLQ-LC13 forms. Disease control was assessed by response evaluation criteria in solid tumors（RECIST）. Results Of 50 cases, 22 cases had partial remission （PR） ,20 cases had stable disease （SD） ,and 8 cases had progressive disease （PD）. Except the social function in the 5-function scales, all other 4 functions and the mean scores of QOL were improved significantly after pemetrexed therapy （P〈0. 05 ）. Mean scores of major general symptoms, like hypodynamia and anorexia, and disease-related symptoms were decreased significantly （P〈0. 05）. Conclusion As a second line treatment, premetrexed not only increases the survival, but also reduces tumor-related symptoms and improves QOL in the advanced-stage NSCLC patients,who have received platium-based regiments previously.